最新ニュース Insulet (NASDAQ:PODD) 株価情報

Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Insulet Corp

Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) (Insulet or the Company), the global leader in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54155373&amp;newsitemid=20241120268759&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=807c8b95f30f75f117e9943595c99975">tubeless insulin pump</a> technology with its Omnipod&#xAE; brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S.

News

PODD

Insulet Announces Omnipod 5 System Is Now Compatible With Abbott's FreeStyle Libre 2 Plus Sensor In The U.S.

WIIM

Insulet shares are trading higher after Morgan Stanley raised its price target on the stock from $234 to $317 while Barclays raised its price target from $220 to $234.

Barclays analyst Matt Miksic maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Equal-Weight and raises the price target from $220 to $234.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Insulet, Raises Price Target to $234

Morgan Stanley analyst Patrick Wood maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Overweight and raises the price target from $234 to $317.

Morgan Stanley Maintains Overweight on Insulet, Raises Price Target to $317

As of Nov. 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Airsculpt Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>)</h3>
<ul>
<li>On Nov. 8, AirSculpt Technologies posted better-than-expected quarterly results. &#8220;Our revenue and Adjusted EBITDA for the quarter were in line with our expectations with the period including progress on our strategy despite continued challenges in the consumer environment,&#8221; said Dennis Dean, Interim Chief Executive Officer and Chief Financial Officer of AirSculpt Technologies, Inc. The company's stock gained around 42% over the past five days and has a <a href="https://www.benzinga.com/quote/AIRS">52-week high of $8.88</a>.</li>
<li>RSI Value: 81.89&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>AIRS Price Action: Shares of Airsculpt Technologies gained 20.7% to close at $8.68 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Quidelortho Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>)</h3>
<ul>
<li>On Nov. 7, QuidelOrtho reported better-than-expected third-quarter financial results and issued FY24 revenue above estimates. &#8220;We delivered solid third quarter results, giving us confidence that our strategic priorities and focus on our customers, business growth and margin improvement are gaining traction,&#8221; said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho. The company's stock gained around 11% over the past five days and <a href="https://www.benzinga.com/quote/QDEL">has a 52-week high</a> of $75.86.</li>
<li>RSI Value: 74.63</li>
<li>QDEL Price Action: Shares of Quidelortho gained 12.6% to close at $43.75 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Nuvation Bio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>)</h3>
<ul>
<li>On Nov. 6, Nuvation Bio reported financial results for the third quarter ended Sept, 30, and provided a business update. David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio stated: &#8220;In the third quarter, we continued to execute on our goal of bringing taletrectinib to people living with ROS1-positive NSCLC as quickly as possible, which has been our focus since we closed the acquisition of AnHeart Therapeutics earlier this year. In October, we completed the rolling submission of our NDA for line agnostic full approval of taletrectinib in advanced ROS1-positive NSCLC, which was supported by the pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies that we presented at ESMO. We believe that these data – a confirmed objective response rate of 89% and median duration of response approaching four years in the TKI-naïve setting – are the strongest data seen to date in the ROS1 space and increase taletrectinib&#8217;s potential to become a best-in-class treatment option.&#8221; The company's stock gained around 25% over the past five days and has a <a href="https://www.benzinga.com/quote/NUVB">52-week high</a> of $4.16.</li>
<li>RSI Value: 71.61</li>
<li>NUVB Price Action: Shares of Nuvation Bio gained 9.9% to close at $2.88 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Insulet Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>)</h3>
<ul>
<li>On Nov. 7, Insulet reported better-than-expected third-quarter financial results. &#8220;We continue to achieve significant milestones and robust revenue growth,&#8221; said Jim Hollingshead, President and Chief Executive Officer. The company's stock jumped around 14% over the past five days and has a 52-week high is $275.52.</li>
<li>RSI Value: 87.19</li>
<li>PODD Price Action: Shares of Insulet gained 9.4% to close at $268.00 on Friday. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41871463/dow-sp-500-notch-best-week-of-year-as-tesla-surges-post-trump-win-investor-sentiment-improves-fear-greed-index-remains-in-neutral-zone">Dow, S&amp;P 500 Notch Best Week Of Year As Tesla Surges Post Trump Win: Investor Sentiment Improves, Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

AIRS

NUVB

QDEL

Top 4 Health Care Stocks That May Plunge This Quarter

The S&amp;P 500 index surged past the 6,000-point milestone, setting fresh record highs, and small-cap stocks are poised for their best weekly performance since April 2024 as investor optimism surrounding the &#8220;Trump trade&#8221; continued to fuel a strong risk-on sentiment by the end of a <a href="https://www.benzinga.com/markets">wild week in the market</a>. 
All major U.S. indices posted modest gains in midday trading, with the Dow Jones Industrial Average leading slightly, soaring beyond the 44,000-point mark. The blue-chip index is set for its best weekly performance in over a year.
Friday's rise in the S&amp;P 500 was powered by the utilities and real estate sectors, which had lagged post-election. Tech stocks took a breather following Thursday's rally.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) surged 7%, pushing its weekly gains beyond 27% and propelling its market cap past $1 trillion. 
This move now places every "Magnificent Seven" tech stock in the trillion-dollar club, with the group's combined market cap topping $17 trillion.
Treasury yields held steady, while the dollar strengthened in response to the Federal Reserve's Thursday 25-basis-point rate <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41823887/powell-dismisses-talk-of-resignation-after-trump-victory-says-policy-is-still-res">cut to 4.5%-4.75%</a>.
Gold softened, eyeing its worst week since late May, as both silver and oil dropped over 2% on the day. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged up 0.8%, extending its weekly gains to over 11%, marking its best week since July.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,993.21</td>
<td>0.6%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,998.81</td>
<td>0.4%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,389.50</td>
<td>0.3%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,124.53</td>
<td>0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:05 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.4% to $598.17.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.6% to $439.89.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) inched 0.1% higher to $514.10.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.3% to $237.08.</li>
<li>The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, rising 1.8%. The Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 1%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports were: 
<ul>
<li>NRG Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>), up 0.5%, </li>
<li>Ubiquiti Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>), up 21%</li>
<li>Arista Networks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NASDAQ">ANET</a>), down 7%, </li>
<li>Airbnb Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), down 7.5%, </li>
<li>Motorola Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>), up 6.7%, </li>
<li>EOG Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>), up 5.9%, </li>
<li>Fortinet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>), up over 9%, </li>
<li>The Trade Desk Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), down over 4%, </li>
<li>Monster Beverage Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>), up by 0.5%, </li>
<li>Axon Enterprise Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>), up 25%, </li>
<li>Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>), down 4.4%, </li>
<li>Cloudfare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), down 6.2%, </li>
<li>Corpay Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>), up 6%, </li>
<li>Expedia Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NYSE">EXPE</a>), up over 6%, </li>
<li>Toast Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>), up 13%, </li>
<li>Pinterest Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>), down 17%, </li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>), up 1.7%, </li>
<li>Insulet Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), up 12%, </li>
<li>News Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWS#NASDAQ">NWS</a>), up 3.6%, </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41848568/us-consumer-sentiment-rises-more-than-predicted-to-6-month-highs-inflation-expectations-hit-4-year-low">US Consumer Sentiment Rises More Than Predicted To 6-Month Highs, Inflation Expectations Hit 4-Year Low</a></li>
</ul>
Illustration created using artificial intelligence via Midjourney.

Equities

Sector ETFs

Movers

ETFs

$BTC

ABNB

ANET

AXON

CPAY

SPDR Dow Jones Industrial Average ETF Trust

DKNG

EXPE

FTNT

MNST

PINS

TOST

TSLA

S&P 500 Breaks 6,000 Points, Dow Soars Above 44,000, Small Caps Eye Strongest Week In 4 Years, Tesla Hits $1 Trillion: What's Driving Markets Friday?

BTIG analyst Marie Thibault maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $260 to $270.

BTIG Maintains Buy on Insulet, Raises Price Target to $270

Insulet shares are trading higher after the company reported better-than-expected Q3 financial results.

Guidance

Insulet Raises FY24 Revenue Growth To Range Of 20% - 21% (Previously 16% -19%)

Insulet Expects Q4 Revenue Growth Of 12% To 15% In Constant Currency

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.76 by 18.42 percent. This is a 26.76 percent increase over earnings of $0.71 per share from the same period last year. The company reported quarterly sales of $543.90 million which beat the analyst consensus estimate of $518.26 million by 4.95 percent. This is a 25.70 percent increase over sales of $432.70 million the same period last year.

Earnings

Earnings Beats

Insulet Q3 2024 Adj EPS $0.90 Beats $0.76 Estimate, Sales $543.90M Beat $518.26M Estimate

Analysts' ratings for Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $260.22, a high estimate of $300.00, and a low estimate of $220.00. Witnessing a positive shift, the current average has risen by 11.92% from the previous average price target of $232.50.
<img src="https://www.benzinga.com/files/images/story/2024/1730908849_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Insulet by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$269.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$223.00</td>
<td>$211.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Insulet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insulet compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Insulet's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PODD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insulet analyst ratings.</a>
<h2>About Insulet</h2>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>Understanding the Numbers: Insulet's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Insulet's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 23.2%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Insulet's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 38.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 21.08%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Insulet's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.85%, the company showcases efficient use of assets and strong financial health.
Debt Management: Insulet's debt-to-equity ratio surpasses industry norms, standing at 1.4. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

9 Analysts Have This To Say About Insulet

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d94a96b85e930001fd9dd4/kevin-dede">HC Wainwright &amp; Co. analyst Kevin Dede</a> initiated coverage on BitFuFu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) with a Buy rating and announced a price target of $7. BitFuFu shares closed at $4.57 on Tuesday. <a href="https://www.benzinga.com/quote/FUFU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst David Katz initiated coverage on Ryman Hospitality Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) with a Buy rating and announced a price target of $130. Ryman Hospitality shares closed at $108.30 on Tuesday. <a href="https://www.benzinga.com/quote/RHP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61826cd080db050001bbb18a/jiong-shao">Barclays analyst Jiong Shao</a> initiated coverage on Vipshop Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) with an Overweight rating and announced a price target of $19. Vipshop shares closed at $14.58 on Tuesday. <a href="https://www.benzinga.com/quote/VIPS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Gary Mobley initiated coverage on Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) with an Overweight rating and announced a price target of $62. Rambus shares closed at $50.26 on Tuesday. <a href="https://www.benzinga.com/quote/RMBS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Lee Hambright initiated coverage on Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with an Outperform rating and announced a price target of $300. Insulet shares closed at $241.32 on Tuesday. <a href="https://www.benzinga.com/quote/PODD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PODD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-1024x582.png" alt="" class="wp-image-632774" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51.png 1178w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Initiation

FUFU

RMBS

VIPS

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Bernstein analyst Lee Hambright initiates coverage on Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Outperform rating and announces Price Target of $300.

Bernstein Initiates Coverage On Insulet with Outperform Rating, Announces Price Target of $300

Retail Sales

Insulet Corporation Announced The Full Market Release Of The Omnipod 5 App For iPhone

<a href="https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions" title="https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions">https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions</a>

AAPL

DXCM

'Apple Staff Tests Blood-Sugar App In Sign Of Health Ambitions' - Bloomberg News

Insulet's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NYSE">PODD</a>) short percent of float has fallen 7.37% since its last report. The company recently reported that it has 2.77 million shares sold short, which is 5.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insulet Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729868425_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insulet has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Insulet's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insulet's peer group average for short interest as a percentage of float is 3.92%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

(PODD) - Analyzing Insulet's Short Interest

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 10 years by 7.86% on an annualized basis producing an average annual return of 19.18%. Currently, Insulet has a market capitalization of $16.55 billion. 
Buying $1000 In PODD: If an investor had bought $1000 of PODD stock 10 years ago, it would be worth $5,810.02 today based on a price of $236.00 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729805415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Insulet 10 Years Ago Would Be Worth Today

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 10 years by 8.03% on an annualized basis producing an average annual return of 19.64%. Currently, Insulet has a market capitalization of $16.22 billion. 
Buying $100 In PODD: If an investor had bought $100 of PODD stock 10 years ago, it would be worth $619.45 today based on a price of $231.32 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729006218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have $600 Today

Ratings for Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $252.89, a high estimate of $285.00, and a low estimate of $220.00. This current average has increased by 8.69% from the previous average price target of $232.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1728936070_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Insulet among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$269.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$223.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$234.00</td>
<td>$234.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Insulet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insulet compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Insulet's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Insulet's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PODD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insulet analyst ratings.</a>
<h2>Delving into Insulet's Background</h2>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>A Deep Dive into Insulet's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Insulet's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.2% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Insulet's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Insulet's ROE excels beyond industry benchmarks, reaching 21.08%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 6.85%, the company showcases effective utilization of assets.
Debt Management: Insulet's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.4, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Insulet

Fidelity Growth Strategies Fund Q3 2024 Review

Fidelity Select Health Care Portfolio Q3 2024 Fund Review

JPMorgan's 'Analyst Focus List' – growth, income, value, short ideas

Insulet's Omnipod 5 now compatible with Abbott's FreeStyle Libre 2 Plus

Citi Research's 'SMID Value' Rec List – CHWY, FHN, PODD, and more

Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines

In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Buy rating on Insulet (PODD – Research Report), with a price t...

Insulet's Strategic Advancements and Market Positioning Drive Buy Rating

Insulet: Superb Business Growth, Starting Valuations Outsized Risk

Franklin Convertible Securities Fund Q3 2024 Commentary

JPMorgan updates its U.S. Analyst Focus List – Adds TPR, ALRM, REG

ABBV

AGCO

ALLY

ALNY

ALRM

AMZN

ARGNF

ARGX

ARMK

ASND

AVGO

BABA

BABAF

BKNG

BRBR

BRKR

BURL

CHWY

CVNA

CYBR

DAWN

DELL

DOCS

DOCU

EWTX

EXAS

GLOB

GTLS

GWRE

HUBS

INSM

ISRG

IVPAF

KLAC

KVUE

LEGN

MKSI

MNDY

MSFT

NTRA

PCVX

PEGA

PLTR

PTON

REXR

ROIV

RVMD

SAIC

SCHW

SIRI

SMMD

SNAP

SNDX

SPGI

SWTX

TFII

TMUS

TRGP

TVTX

ULTA

VERA

VICI

WELL

WOLF

XENE

Press Releases

Insulet to Present at Upcoming Investor Conferences

Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024

Entertainment

General

National Campaign Launches to Combat Diabetes Stigma Using Comedy

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

Omnipod® 5 App for iPhone® Now Fully Available in the United States

Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November

Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S.

Comments

Insulet

ニュース

最新ニュース Insulet (NASDAQ:PODD) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル